CIBC Private Wealth Group
KPTI icon

CIBC Private Wealth Group’s Karyopharm Therapeutics KPTI Stock Holding History

CIBC Private Wealth Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$22 Hold
3
– – ﹤0.01% 3361
2025
Q3 		$20 Hold
3
– – ﹤0.01% 3047
2025
Q2 		$13 Hold
3
– – ﹤0.01% 3043
2025
Q1 		$12 Hold
3
– – ﹤0.01% 3049
2024
Q4 		$36 Hold
3
– – ﹤0.01% 2929
2024
Q3 		$42 Hold
3
– – ﹤0.01% 3067
2024
Q2 		$40 Hold
3
– – ﹤0.01% 3109
2024
Q1 		$79 Buy
+3
New +$53 ﹤0.01% 3015

Other funds holding KPTI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return

CIBC Private Wealth Group's KPTI Position: Q4 2025 in Review

CIBC Private Wealth Group held its Karyopharm Therapeutics (KPTI) position steady in Q4 2025 at 3 shares worth $22. The position accounts for ﹤0.01% of the portfolio, ranked #3361.

CIBC Private Wealth Group first reported a position in KPTI in Q1 2024 and has held it in 8 quarters since. The position peaked at $79 in Q1 2024. 69 funds tracked by Wall St. Rank hold KPTI as of Q4 2025.

  • CIBC Private Wealth Group held 3 shares of Karyopharm Therapeutics worth $22 as of Q4 2025.
  • CIBC Private Wealth Group left its Karyopharm Therapeutics share count unchanged in Q4 2025.
  • Karyopharm Therapeutics made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #3361 holding.
  • CIBC Private Wealth Group first reported a position in Karyopharm Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • CIBC Private Wealth Group's Karyopharm Therapeutics position peaked at $79 in Q1 2024.
  • 69 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.